Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
暂无分享,去创建一个
William Pao | Yumei Pan | Lu Wang | Elisa de Stanchina | Marc Ladanyi | Cindy L Vnencak-Jones | Lynnette Fernandez-Cuesta | Maria E Arcila | Gregory J Riely | Juliann Chmielecki | M. Ladanyi | M. Kris | S. Toyooka | W. Pao | L. Sequist | J. Engelman | M. Arcila | D. Dias-Santagata | P. Fidias | Gregory Riely | V. Miller | K. Kiura | K. Shien | J. Yang | L. Fernandez-Cuesta | E. de Stanchina | C. Vnencak-Jones | J. Chmielecki | T. Morán | Ya-Lun Lin | Jeffrey A Engelman | Shinichi Toyooka | Teresa Moran | Mark G Kris | Vincent A Miller | Katsuyuki Kiura | K. Ohashi | Dora Dias-Santagata | Lecia V Sequist | James Chih-Hsin Yang | K. Aoe | Lu Wang | Keisuke Aoe | Panos Fidias | Kadoaki Ohashi | Ya-Lun Lin | Kazuhiko Shien | Yumei Pan
[1] Y. Maehara,et al. Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer , 2010, Clinical Cancer Research.
[2] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[3] Antonio Marchetti,et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] N. Socci,et al. Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.
[5] M. Ladanyi,et al. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay , 2011, Clinical Cancer Research.
[6] W. Lam,et al. PIK3CA mutations and copy number gains in human lung cancers. , 2008, Cancer research.
[7] William Pao,et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.
[8] H. Groen,et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[10] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[11] William Pao,et al. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.
[12] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[13] K. Kiura,et al. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. , 2009, Cancer research.
[14] M. Ladanyi,et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[16] Y. Maehara,et al. Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[18] R. Wilson,et al. Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4 , 2007, PloS one.
[19] Narasimhan P. Agaram,et al. Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors , 2008, Genes, chromosomes & cancer.
[20] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[21] S. Gabriel,et al. High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.
[22] L. Tanoue. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .
[23] K. Kiura,et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. , 2007, Cancer research.
[24] William Pao,et al. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors , 2006, Clinical Cancer Research.
[25] M. Ladanyi,et al. Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling , 2011, Molecular Cancer Therapeutics.
[26] A. Gemma,et al. F1000 highlights , 2010 .
[27] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[28] A. Iafrate,et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. , 2011, The Journal of molecular diagnostics : JMD.
[29] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[30] M. Meyerson,et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.
[31] G. Giaccone,et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[33] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[34] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Ladanyi,et al. EGFR mutations in small-cell lung cancers in patients who have never smoked. , 2006, The New England journal of medicine.
[36] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[37] H. Varmus,et al. Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma , 2010, Disease Models & Mechanisms.
[38] M. Tsuboi,et al. Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib , 2006, Clinical Cancer Research.
[39] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[40] William Pao,et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. , 2009, The Journal of clinical investigation.
[41] Li Ding,et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. , 2008, Cancer research.
[42] S. Digumarthy,et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] David N Louis,et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine , 2010, EMBO molecular medicine.